Everyone thought Moderna was finished. 😂
MRNA had fallen massively from its pandemic-era high, dropping from around $484 to near $64.
Then one major Phase 3 result changed the story. 🚀
Moderna jumped nearly 177% in one session after positive results from its personalized mRNA cancer treatment with Merck’s Keytruda for high-risk melanoma.
That’s biotech for you — one major clinical update can completely change market sentiment.
It’s also interesting to see mRNA technology being explored beyond vaccines and into cancer treatment.
Now the big question is whether MRNA can hold this momentum or if traders will start taking profits. 👀
I’m keeping an eye on the chart and watching the volatility on BingX.
Biotech moves can be wild, so risk management matters.
#Moderna #MRNA
MRNA had fallen massively from its pandemic-era high, dropping from around $484 to near $64.
Then one major Phase 3 result changed the story. 🚀
Moderna jumped nearly 177% in one session after positive results from its personalized mRNA cancer treatment with Merck’s Keytruda for high-risk melanoma.
That’s biotech for you — one major clinical update can completely change market sentiment.
It’s also interesting to see mRNA technology being explored beyond vaccines and into cancer treatment.
Now the big question is whether MRNA can hold this momentum or if traders will start taking profits. 👀
I’m keeping an eye on the chart and watching the volatility on BingX.
Biotech moves can be wild, so risk management matters.
#Moderna #MRNA